Besides vaccines, mRNA technology is being explored for
therapeutic applications in oncology, infectious diseases, genetic
disorders, and other areas. This diversification expands the market
potential.
WILMINGTON, Del., July 22, 2024 /PRNewswire/ -- The mRNA
vaccines and therapeutics market was projected to attain
US$ 19.6 billion in 2023. It is
likely to garner a 14.6% CAGR from 2024 to 2034,
and by 2034, the market is expected to attain US$ 85.9 billion.
Continuous advancements in mRNA delivery systems, lipid
nanoparticle formulations, and manufacturing processes are
improving efficacy, safety, and scalability, driving market growth.
Initiatives to improve global health and vaccine
accessibility, combined with partnerships between governments,
NGOs, and pharmaceutical companies, are expanding the reach of mRNA
vaccines in developing countries.
Increased public awareness and acceptance of mRNA technology are
driving demand for future mRNA-based therapeutics. mRNA technology
allows for personalized approaches in medicine, such as tailored
cancer vaccines based on individual genetic profiles. This trend
towards precision medicine enhances therapeutic efficacy and
patient outcomes.
Download Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86317
MRNA Vaccines and Therapeutics Market: Key Players
The competitive landscape of the mRNA vaccines and therapeutics
market is dynamic and evolving, characterized by a mix of
established pharmaceutical companies, biotechnology firms, and
emerging players.
The following companies are well known participants in the mRNA
vaccines and therapeutics market:
- Moderna Inc.
- BioNTech SE.
- CureVac SE
- Arcturus Therapeutics Inc.
- Sanofi
- GSK plc
- Argos Therapeutics Inc.
- Ethris
- Pfizer Inc.
- AstraZeneca
Key Developments
- In 2022, CSL Limited announced that its subsidiary, CSL
Seqirus, finalized a global collaboration and license agreement
with Arcturus Therapeutics Holdings Inc. This agreement
provides CSL Seqirus access to Arcturus Therapeutics' advanced
self-amplifying mRNA (sa-mRNA) vaccine platform technology.
- In the same year, Moderna, Inc., a biotechnology company at
the forefront of messenger RNA (mRNA) therapeutics and
vaccines, announced it had received emergency use authorization
(EUA) from the U.S. Food and Drug Administration (FDA) for its
BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine,
mRNA-1273.222, for children aged six months to five years.
The increasing incidence of chronic diseases like cancer,
diabetes, and cardiovascular disorders is driving demand for novel
therapeutic approaches, including mRNA-based treatments targeting
these conditions. Integration of mRNA technology with other
advanced technologies like CRISPR-Cas9 for gene editing or with
digital health platforms for real-time monitoring is opening new
avenues for therapeutic interventions and patient management.
Investments in scaling up mRNA manufacturing capacity and
improving production efficiency are addressing supply chain
challenges and meeting global demand for vaccines and therapeutics.
Shift towards patient-centric healthcare models, where treatments
are tailored to individual patient needs and preferences, aligns
with the personalized nature of mRNA therapies, thereby driving
market adoption.
mRNA Vaccines and Therapeutics Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 19.6 Bn
|
Forecast (Value) in
2034
|
US$ 85.9 Bn
|
Growth Rate
(CAGR)
|
14.6 %
|
No. of
Pages
|
153
Pages
|
Segments
covered
|
By mRNA Type, By Type,
By Application, By End-user, By Region
|
Key Findings of Market Report
- Investments in education and training programs for healthcare
professionals and researchers on mRNA technology and its
applications are fostering expertise and capability building across
the industry.
- Integration of artificial intelligence (AI) and machine
learning (ML) algorithms for data analysis, predictive modeling,
and personalized treatment optimization is enhancing the
development and deployment of mRNA therapies.
- Focus on rare diseases and orphan drug designation for
mRNA-based therapies presents niche market opportunities, supported
by regulatory incentives and high unmet medical needs in these
patient populations.
- Exploration of mRNA vaccines' potential for providing long-term
immunity and development of booster shots against emerging variants
of pathogens like SARS-CoV-2 is driving continuous market demand
and innovation.
Market Trends for MRNA Vaccines and Therapeutics
- By mRNA type, the nucleoside-modified mRNA segment is expected
to boost the growth of the MRNA vaccines and therapeutics market.
Nucleoside modifications improve mRNA stability against enzymatic
degradation and enhance its translational efficiency within cells.
This results in higher protein expression levels, which is crucial
for the effectiveness of vaccines and therapeutics.
- Modifications such as pseudouridine reduce the innate immune
response triggered by mRNA molecules, thereby enhancing safety and
reducing adverse reactions in recipients. Nucleoside-modified mRNA
technology enables the development of vaccines and therapeutics
targeting a wider range of diseases, including infectious diseases,
cancer immunotherapy, and genetic disorders. This versatility
expands market opportunities.
- mRNA vaccines are relatively easier and faster to manufacture
compared to traditional vaccines, allowing for rapid scale-up and
distribution during outbreaks or pandemics. Growing acceptance and
adoption of mRNA technology by pharmaceutical companies,
governments, and public health agencies support ongoing research,
development, and deployment of prophylactic vaccines.
Explore Sample of the Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86317
Global Market for MRNA Vaccines and Therapeutics: Regional
Outlook
North America
- North America boasts robust
research institutions, biotechnology companies, and academic
collaborations that support the advancement of mRNA vaccines and
therapeutics. Access to funding and expertise accelerates product
development timelines.
- Government agencies in North
America, such as the NIH (National Institutes of Health) and
BARDA (Biomedical Advanced Research and Development Authority),
provide substantial funding and regulatory incentives to accelerate
mRNA vaccine research, development, and manufacturing.
Asia Pacific
- Asia Pacific is becoming a hub
for biopharmaceutical manufacturing and research. Local production
capabilities and expertise in genetic engineering and biotechnology
support the development and scale-up of mRNA-based products.
- The region offers diverse patient populations for clinical
trials, enabling rapid evaluation of mRNA vaccines and therapeutics
across different demographics and disease profiles.
MRNA Vaccines and Therapeutics Market Segmentation
mRNA Type
- Nucleoside-modified mRNA
- Unmodified mRNA
- Self-amplifying mRNA
Type
Application
- Infectious Diseases
- Oncology
- Rare Genetic Diseases
- Others (Respiratory Diseases, etc.)
End User
- Hospitals & Clinics
- Biopharmaceutical Companies
- Others (Research Organizations, etc.)
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Buy this Premium Research Report:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86317<ype=S
More Trending Report by Transparency Market Research:
• Electronic Health Records Market likely to
surpass USD 50 Bn by 2031,
expanding at a 5% CAGR
• IV Bags Market Predicted to Reach
USD 1.5 billion by 2032, Expanding at
a CAGR of 5.8%
• Contact and Intraocular Lenses Market is expected
to grow at a CAGR of 6.4% from 2024 to 2034 and reach US$ 22.9 Bn by the end of 2034
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington,
Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow
Us: LinkedIn| Twitter| Blog | YouTube
Logo -
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mrna-vaccines-and-therapeutics-market-to-reach-us-85-9-billion-garnering-a-14-6-cagr-by-2034-transparency-market-research-inc-302202941.html